Holen Sie sich die Stockscreener-App
2.31
1.70%
-0.04
Handel nachbörslich:
2.31
Veru Inc Aktie (VERU) Neueste Nachrichten
Veru 2Q Loss $2.74M >VERU - Moomoo
Nvidia (NVDA) CEO Discusses Arrival of Veru CPUs in AI Labs - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
VERU Maintained by Oppenheimer -- Price Target Lowered to $24 - GuruFocus
Oppenheimer Adjusts Price Target on Veru to $24 From $25, Maintains Outperform Rating - marketscreener.com
Veru Inc. Earnings Call Highlights Clinical Momentum - The Globe and Mail
Veru 2Q Loss/Shr 12c >VERU - Moomoo
Veru Inc. (NASDAQ:VERU) Q2 2026 Earnings Call Transcript - Insider Monkey
Veru outlines Q1 2027 interim readout for 36-week enobosarm plateau analysis - MSN
Veru SEC Filings - Stock Titan
Veru Inc (VERU) Q2 2026 Earnings Call Highlights: Promising Clin - GuruFocus
Veru Q2 2026: -$0.12 EPS Tops Estimates — Deep Dive - AlphaStreet
Q2 2026 Veru Inc Earnings Call Transcript - GuruFocus
Veru Inc. (VERU) Reports Positive Phase IIb Trial Results and On - GuruFocus
Veru (VERU) Q2 2026 Earnings Transcript - AOL.com
Veru Posts Narrower Q2 2026 Loss of -$0.12, 57.1% Better Than Forecast - AlphaStreet
Veru Q2 2026 earnings preview - MSN
Veru Releases Q2 2026 Financial Results - AlphaStreet
Veru Inc. 2026 Q2 Financial Report: Key Risks, Results, and Clinical Trial Updates - Minichart
Veru Reports Q2 2026 Results and Progress on Phase 2b PLATEAU Trial for Enobosarm Plus Semaglutide in Obesity Treatment - Minichart
Veru reports Q2 fiscal 2026 results, obesity trial enrolling By Investing.com - Investing.com India
Veru Inc. (VERU) Reports Q2 Earnings, EPS Exceeds Expectations - GuruFocus
Veru Inc (VERU.US) is scheduled to release its earnings report on May 13. - 富途牛牛
VERU: Phase II-B data show enobosarm preserves muscle and function, with improved financials and strong cash - TradingView
VERU Reports Financial Growth and Clinical Trial Progress - GuruFocus
Veru Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Veru Inc Q2 2026 shows improved financials - Investing.com
VERU: Enobosarm preserves muscle and function in older obese patients; losses narrowed, cash improved - TradingView
Earnings call transcript: Veru Inc Q2 2026 shows improved financials By Investing.com - Investing.com Nigeria
VERU INC. 3Q 2026: Revenue $0 Net loss $2.74M, EPS $(0.12) — 10-Q Summary - TradingView
Veru (NASDAQ: VERU) narrows loss but warns on going concern and funding needs - Stock Titan
Transcript: Veru Q2 2026 Earnings Conference Call - Yahoo Finance
Veru reports Q2 fiscal 2026 results, obesity trial enrolling - Investing.com UK
Veru reports Q2 fiscal 2026: Net loss narrows to $2.7M, cash $27.6M - TradingView
Veru (VERU) trims losses and advances PLATEAU Phase 2b obesity trial - Stock Titan
Veru Inc. Announces Active Enrollment in Phase 2b PLATEAU Study of Enobosarm and Semaglutide with Interim Analysis Expected in 2027 - Quiver Quantitative
Veru obesity trial tests add-on to semaglutide to break weight-loss plateau - Stock Titan
Press Release: Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress - Moomoo
TradingKey - TradingKey
Veru Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):